PR Newswire
London, May 1
Press Release
www.shire.com
Director/PDMR Share Dealings
May 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces it
was notified today that on April 30, 2015, Stock Appreciation Rights ("SARs")
and Restricted Stock Units ("RSUs") were granted to Persons Discharging
Managerial Responsibilities ("PDMRs") under the Shire Long Term Incentive Plan
2015 ("LTIP"). SARs and RSUs will normally vest after three years, subject to
any performance conditions being satisfied, with no consideration payable on
these awards. The awards were granted over notional American Depositary Shares
("ADSs") in the Company as follows:
PDMR Type of Award Number of ADSs Exercise Price
(1),(2) (3)
Flemming Ornskov SAR 26,398 $245.48
RSU 19,799 Nil
Jeff Poulton SAR 8,862 $245.48
RSU 6,646 Nil
Mark Enyedy SAR 4,444 $245.48
RSU 4,191 Nil
Ginger Gregory SAR 4,259 $245.48
RSU 4,016 Nil
Phil Vickers SAR 4,259 $245.48
RSU 4,016 Nil
1. SARs and RSUs granted under the LTIP correspond to SARs and Performance
Share Awards ("PSAs") granted under the legacy Shire Portfolio Share Plan,
as referenced in the Directors' Remuneration Report in the 2014 Annual
Report and Accounts.
2. SARs and RSUs granted to Dr. Ornskov and Mr. Poulton and RSUs granted to
the remainder of the PDMRs are subject to performance conditions. Upon
normal vesting, any ADSs to be delivered to Dr. Ornskov and Mr. Poulton
will be subject to a retention period of two years in accordance with the
rules of the LTIP.
3. One ADS is equal to three Ordinary Shares of 5 pence each in the Company.
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
